SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September
8, 2023 (
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction
|(Commission File Number)||(IRS Employer|
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02 Termination of Material Definitive Agreement.
As previously disclosed on a Current Report on Form 8-K filed by Nektar Therapeutics (“Nektar”) with the U.S. Securities and Exchange Commission on April 14, 2022, Nektar and Bristol-Myers Squibb Company (“BMS”) jointly decided to end the global clinical development program evaluating Nektar’s proprietary drug candidate bempegaldesleukin in combination with BMS’s Opdivo® (nivolumab) (“Opdivo”) pursuant to a Strategic Collaboration Agreement, dated February 13, 2018. On September 6, 2023, the parties entered into a letter agreement (the “Letter Agreement”) to terminate the Strategic Collaboration Agreement. The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the Strategic Collaboration Agreement as amended and previously filed, and the Letter Agreement, a copy of which will be filed as an exhibit to Nektar’s Quarterly Report on Form 10-Q for the fiscal quarter period ending September 30, 2023.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: September 8, 2023||By:||/s/ Mark A. Wilson|
|Mark A. Wilson|
|Chief Legal Officer and Secretary|